1. Roehrborn CG, McConnell JD. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, Kavoussi LR, Novick AC, et al, editors. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Campbell's urology. 2002. 8th ed. Philadelphia: WB Saunders; pp. 1297-1336.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479. PMID:
6206240.
3. Gu FL, Xia TL, Kong XT. Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China. Urology 1994;44:688-691. PMID:
7526525.
4. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256-1261. PMID:
15758764.
5. McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, et al. Benign prostatic hyperplasia: diagnosis and treatment (Clinical practice guideline no. 8; AHCPR publication no. 94-0582). 1994. Rockville: U.S.: Department of Health and Human Services, Agency for Healthcare Research and Quality.
6. Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996;29:15-20. PMID:
8821684.
7. Yu P, Zheng H, Su H, Zuo T, Duan C, Gao F, et al. Prevalence of prostatic hyperplasia and its relative factors in six cities of China in 1997. Zhonghua Liu Xing Bing Xue Za Zhi 2000;21:276-279. PMID:
11860799.
8. Gravas S, Tzortzis V, Melekos MD. Translation of benign prostatic hyperplasia guidelines into clinical practice. Curr Opin Urol 2008;18:56-60. PMID:
18090491.
9. Irani J, Brown CT, van der Meulen J, Emberton M. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 2003;92:937-942. PMID:
14632851.
10. Kim HL, Benson DA, Stern SD, Gerber GS. Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey. Urology 2002;59:266-271. PMID:
11834400.
11. Fukagai T, Maruyama K, Nagata M, Morita M, Naoe M, Yoshida H. Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners. Int J Urol 2007;14:412-415. PMID:
17511723.
12. Hutchison A, Farmer R, Chapple C, Berges R, Pientka L, Teillac P, et al. Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol 2006;50:555-561. PMID:
16782265.
13. Paick JS, Kim SW, Ku JH. Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines. Yonsei Med J 2007;48:281-288. PMID:
17461528.
14. Physicians' desk reference. 2007. 61st ed. Montvale: Thomson PDR.
15. Lin T. Market analysis of medicines for treatment of benign prostatic hyperplasia in sample hospitals of Shanghai. Pharm Care Res 2006;6:370-372.
16. Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999;54:670-678. PMID:
10510926.
17. Kaplan SA, Lee JY, Meehan AG, Kusek JW. MTOPS Research Group. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 2011;185:1369-1373. PMID:
21334655.
18. Vickers AJ, Savage CJ, Lilja H. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol 2010;28:1112-1116. PMID:
20124185.
19. Speakman MJ. Integrating patient risk profiles in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in Clinical Practice. Eur Urol Suppl 2004;3:18-22.
20. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398. PMID:
14681504.
21. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 2006;175:217-220. PMID:
16406915.
22. Lee JY, Lee SH, Kim SJ, Kim CS, Lee HM, Kim CI, et al. Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. Urology 2011;77:171-176. PMID:
20691464.